STOCK TITAN

Cyclacel Pharmaceuticals, Inc - $CYCC STOCK NEWS

Welcome to our dedicated page for Cyclacel Pharmaceuticals news (Ticker: $CYCC), a resource for investors and traders seeking the latest updates and insights on Cyclacel Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cyclacel Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cyclacel Pharmaceuticals's position in the market.

Rhea-AI Summary
Cyclacel Pharmaceuticals, Inc. (CYCC, CYCCP) has regained compliance with the minimum bid price requirement set forth by Nasdaq, ensuring continued listing on the Nasdaq Capital Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.11%
Tags
none
-
Rhea-AI Summary
Cyclacel Pharmaceuticals, Inc. (CYCC, CYCCP) announced that Spiro Rombotis, President & CEO, will present an overview of its business and provide updates on its clinical programs at Biotech Showcase on January 8-10, 2024, in San Francisco, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences
-
Rhea-AI Summary
Cyclacel Pharmaceuticals, Inc. (CYCC, CYCCP) announced a registered direct offering of 388,200 shares of common stock at $3.315 per share, along with unregistered warrants to purchase up to 388,200 shares at $3.19 per share, expected to close on Dec. 22, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.89%
Tags
none
Rhea-AI Summary
Cyclacel Pharmaceuticals, Inc. (CYCC) announced positive interim results from its Phase 1 study of fadraciclib (fadra) in patients with advanced solid tumors and lymphoma. Fadra showed promising anticancer activity as a single agent, especially in patients with CDKN2A, CDKN2B and/or MTAP deletions. The company also reported encouraging results from its plogosertib dose escalation study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
-
Rhea-AI Summary
Cyclacel Pharmaceuticals, Inc. (CYCC, CYCCP) will implement a 1-for-15 Reverse Stock Split of its common stock to comply with the minimum bid price requirement for maintaining its listing on The Nasdaq Capital Market. The Reverse Stock Split will reduce the outstanding common stock from approximately 12.6 million shares to approximately 0.84 million shares, impacting all holders of the Company’s common stock proportionally. Equiniti Trust Company, LLC, is acting as exchange agent for the Reverse Stock Split.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
none
-
Rhea-AI Summary
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) has regained compliance with Nasdaq Listing Rule 5250(c)(1) by filing its quarterly report on Form 10-Q for the period ended September 30, 2023, on November 29, 2023. The Nasdaq Stock Market LLC has closed the matter, indicating positive regulatory compliance for the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Cyclacel Pharmaceuticals, Inc. (CYCC, CYCCP) received a notice of non-compliance from Nasdaq for not filing its quarterly report on time, impacting its compliance with Nasdaq Listing Rule 5250(c)(1). The company has until January 20, 2024, to submit a plan to regain compliance and until May 20, 2024, to actually regain compliance, with no immediate effect on its securities' listing or trading.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) expects to release updated Phase 1/2 clinical and biomarker data for oral Fadraciclib and provide safety, efficacy, and mechanism update for oral Plogosertib. The company reported third quarter financial results, including cash equivalents of $5.9 million as of September 30, 2023, and net loss of $6.1 million for the same period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-34.62%
Tags
-
Rhea-AI Summary
Cyclacel Pharmaceuticals, Inc. will release its third quarter 2023 financial results on November 13, 2023, and host a conference call and live webcast the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.35%
Tags
Rhea-AI Summary
Cyclacel Pharmaceuticals, Inc. announces Q2 financial results and business update. Expects to release Phase 1/2 data for oral Fadraciclib and signals of single-agent efficacy for oral Plogosertib. Cash equivalents at $10.2 million. Available cash to fund planned programs through end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Cyclacel Pharmaceuticals, Inc

Nasdaq:CYCC

CYCC Rankings

CYCC Stock Data

2.99M
1.15M
6.33%
15.37%
1.85%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BERKELEY HEIGHTS

About CYCC

cyclacel limited is a pharmaceuticals company located in 46-48 e smithfield, london, united kingdom.